Yellow Fever (Flaviviruses)

Overview


Plain-Language Overview

Yellow Fever (Flaviviruses) is a viral illness transmitted by infected mosquitoes that primarily affects the liver and blood vessels. It causes symptoms such as fever, jaundice (yellowing of the skin and eyes), and muscle pain. The virus can lead to severe complications including bleeding and organ failure. This disease mainly impacts the circulatory system and can cause life-threatening damage if not recognized. It is most common in tropical regions of Africa and South America where the mosquito vectors thrive.

Clinical Definition

Yellow Fever (Flaviviruses) is an acute viral hemorrhagic disease caused by the yellow fever virus, a member of the Flavivirus genus transmitted by Aedes mosquitoes. The core pathology involves viral replication in the liver leading to hepatocellular necrosis, jaundice, and a systemic inflammatory response. The disease progresses through an initial febrile phase followed by a toxic phase characterized by hemorrhage, renal failure, and multi-organ dysfunction. The infection is significant due to its potential for rapid progression to severe disease and high mortality. Diagnosis and prevention are critical in endemic areas to reduce outbreaks.

Inciting Event

  • Bite from an infected Aedes or Haemagogus mosquito introduces yellow fever virus into the bloodstream.

  • Introduction of virus into a non-immune host initiates infection.

Latency Period

  • The incubation period is typically 3 to 6 days after the mosquito bite.

  • Symptoms usually develop within 1 week of exposure.

Diagnostic Delay

  • Early symptoms mimic common viral illnesses leading to misdiagnosis as dengue or malaria.

  • Lack of awareness and limited access to specific serologic or PCR testing delays diagnosis.

  • Overlap with other hemorrhagic fevers complicates clinical recognition.

Clinical Presentation


Signs & Symptoms

  • High fever with sudden onset and chills.

  • Severe headache and retro-orbital pain.

  • Muscle pain and backache commonly reported.

  • Nausea, vomiting, and abdominal pain indicating gastrointestinal involvement.

  • Jaundice developing in the toxic phase due to liver failure.

  • Bleeding manifestations such as epistaxis, hematemesis, or melena in severe disease.

History of Present Illness

  • Initial phase presents with sudden onset of high fever, chills, headache, myalgia, and back pain.

  • After a brief remission, a toxic phase may develop with jaundice, hemorrhage, vomiting (sometimes with blood), and renal failure.

  • Patients may report fatigue, nausea, and abdominal pain during the toxic phase.

Past Medical History

  • Lack of prior yellow fever vaccination is a key historical factor.

  • History of travel to or residence in endemic areas is relevant.

  • Previous immunosuppressive conditions or therapies may influence disease severity.

Family History

  • There are no known hereditary or familial syndromes associated with yellow fever.

  • Family history is generally not contributory to disease risk or presentation.

Physical Exam Findings

  • Jaundice indicating hepatic involvement and liver dysfunction.

  • Conjunctival injection and hyperemia reflecting systemic viral infection.

  • Hemorrhagic manifestations such as petechiae, ecchymoses, or bleeding from mucous membranes.

  • Tachycardia and hypotension in severe cases indicating shock.

  • Hepatomegaly and tenderness on abdominal exam due to liver inflammation.

Diagnostic Workup


Diagnostic Criteria

Diagnosis is established by detecting yellow fever virus RNA via RT-PCR or identifying IgM antibodies specific to the virus in serum. Clinical suspicion arises in patients with a compatible travel or exposure history presenting with fever, jaundice, and hemorrhagic manifestations. Liver function tests typically show elevated transaminases with a characteristic AST > ALT pattern. Confirmatory diagnosis relies on laboratory testing due to overlapping symptoms with other viral hemorrhagic fevers.

Pathophysiology


Key Mechanisms

  • Infection with yellow fever virus, a single-stranded RNA flavivirus, leads to viral replication in lymph nodes and subsequent viremia.

  • Hepatocellular injury occurs due to direct viral cytopathic effects and immune-mediated damage, causing jaundice and coagulopathy.

  • Endothelial dysfunction and vascular leakage contribute to hemorrhagic manifestations and shock.

  • Immune response dysregulation results in systemic inflammation and multiorgan failure in severe cases.

InvolvementDetails
Organs

Liver is critically involved with hepatocellular necrosis causing jaundice and impaired coagulation.

Kidneys may suffer acute injury due to shock and multiorgan failure.

Heart can be affected by myocarditis contributing to hemodynamic instability.

Tissues

Liver tissue is the primary site of viral replication and damage causing jaundice and coagulopathy.

Vascular endothelium is damaged leading to increased permeability and hemorrhage.

Cells

Kupffer cells in the liver are primary targets for viral replication and contribute to hepatic inflammation.

Hepatocytes undergo necrosis leading to liver dysfunction and jaundice.

Monocytes and macrophages mediate immune response and cytokine release contributing to systemic symptoms.

Chemical Mediators

Interleukin-6 (IL-6) is elevated and contributes to systemic inflammatory response.

Tumor necrosis factor-alpha (TNF-α) mediates endothelial damage and vascular leakage.

Complement activation contributes to tissue injury and hemorrhagic manifestations.

Treatments


Pharmacological Treatments

Non-pharmacological Treatments

  • Supportive care including intravenous fluids to maintain hydration and electrolyte balance.

  • Use of oxygen therapy and mechanical ventilation if respiratory failure develops.

  • Monitoring and management of hepatic and renal function to address organ failure complications.

  • Avoidance of NSAIDs and aspirin to reduce risk of bleeding due to hemorrhagic manifestations.

Prevention


Pharmacological Prevention

  • Live-attenuated yellow fever vaccine providing long-lasting immunity.

  • No specific antiviral therapy is available; vaccination remains the primary pharmacological prevention.

Non-pharmacological Prevention

  • Avoidance of mosquito exposure through use of insect repellents and protective clothing.

  • Elimination of mosquito breeding sites to reduce vector populations.

  • Use of bed nets and window screens in endemic areas.

  • Public health measures including surveillance and outbreak control.

Outcome & Complications


Complications

  • Fulminant hepatic failure leading to multi-organ dysfunction.

  • Hemorrhagic diathesis causing severe bleeding and shock.

  • Acute renal failure secondary to shock or direct viral injury.

  • Myocarditis and cardiac arrhythmias in severe cases.

  • Secondary bacterial infections due to immune compromise.

Short-term Sequelae Long-term Sequelae
  • Prolonged jaundice and hepatic enzyme elevation during recovery.

  • Post-viral fatigue and myalgia lasting weeks to months.

  • Transient renal impairment resolving with supportive care.

  • Chronic hepatic fibrosis or cirrhosis in rare cases after severe liver injury.

  • Persistent renal dysfunction following acute kidney injury.

  • Neurological sequelae such as cognitive impairment or neuropathies are uncommon but possible.

Differential Diagnoses


Yellow Fever (Flaviviruses) versus Dengue Fever

Yellow Fever (Flaviviruses)

Dengue Fever

Travel to endemic areas with transmission by Aedes mosquitoes, often in jungle or sylvatic cycles

Recent travel to tropical areas with Aedes mosquito exposure but often urban settings

Biphasic illness with initial fever followed by jaundice, hemorrhagic manifestations, and potential hepatic failure

Biphasic fever with severe myalgias and rash but rarely causes jaundice or hemorrhagic hepatitis

Thrombocytopenia with elevated liver enzymes and direct hyperbilirubinemia

Marked thrombocytopenia with hemoconcentration and elevated hematocrit

Positive yellow fever virus PCR or IgM serology

Positive dengue NS1 antigen or IgM serology

Yellow Fever (Flaviviruses) versus Viral Hepatitis (Hepatitis A or E)

Yellow Fever (Flaviviruses)

Viral Hepatitis (Hepatitis A or E)

Transmission via mosquito bite in endemic tropical areas

Fecal-oral transmission through contaminated food or water in endemic regions

Acute hepatitis with hemorrhagic fever and potential multi-organ failure

Acute self-limited hepatitis without hemorrhagic fever or renal involvement

Elevated transaminases with coagulopathy and thrombocytopenia

Elevated transaminases with predominantly hepatocellular injury pattern and no coagulopathy initially

Positive yellow fever virus PCR or IgM antibodies

Positive anti-HAV IgM or anti-HEV IgM antibodies

Yellow Fever (Flaviviruses) versus Malaria

Yellow Fever (Flaviviruses)

Malaria

Travel to endemic areas with Aedes mosquito exposure, often jungle or forested regions

Travel to endemic areas with Anopheles mosquito exposure, often rural or peri-urban

Biphasic fever with jaundice, hemorrhagic manifestations, and hepatic injury

Cyclic fevers with chills and sweats, anemia, and splenomegaly without jaundice or hemorrhagic fever

Thrombocytopenia with elevated liver enzymes and no parasites on blood smear

Anemia with parasitized red blood cells on peripheral smear

Positive yellow fever virus PCR or IgM serology

Positive blood smear for Plasmodium species or rapid antigen test

Yellow Fever (Flaviviruses) versus Leptospirosis

Yellow Fever (Flaviviruses)

Leptospirosis

Exposure to mosquito bites in endemic jungle or forested areas

Exposure to contaminated water or animal urine in tropical/subtropical areas

Biphasic illness with fever, jaundice, hemorrhagic fever, and hepatic failure

Biphasic illness with fever, myalgias, conjunctival suffusion, and possible renal failure

Marked transaminase elevation with coagulopathy and thrombocytopenia

Elevated creatinine with mild transaminase elevation and thrombocytopenia

Positive yellow fever virus PCR or IgM serology

Positive microscopic agglutination test or PCR for Leptospira

Yellow Fever (Flaviviruses) versus Typhoid Fever

Yellow Fever (Flaviviruses)

Typhoid Fever

Mosquito bite exposure in endemic tropical regions

Ingestion of contaminated food or water in endemic areas

Biphasic fever with hemorrhagic manifestations and jaundice

Gradual onset of sustained fever, abdominal pain, and rose spots without hemorrhagic fever

Thrombocytopenia with elevated liver enzymes and negative bacterial cultures

Leukopenia with relative bradycardia and positive blood cultures for Salmonella typhi

Positive yellow fever virus PCR or IgM serology

Positive blood culture for Salmonella typhi or Widal test

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.